Vaccine maker Moderna (MRNA) became a household name in the past two years. A sell-side firm upgraded their fundamental opinion of MRNA to "buy" from "hold" Thursday. With the shares rallying, let's check how the charts are doing.
In the daily bar chart of MRNA, below, we can see that buyers have been attracted to the stock in the $125 area since early March. Dips below $125 in May and June were bought. More recently, in late August and early September, buyers came in front of the $125 zone.
The trading volume has been more positive since March and the On-Balance-Volume (OBV) line shows improvement from June. The trend-following Moving Average Convergence Divergence (MACD) oscillator is below the zero line but has narrowed towards a possible cover shorts buy signal.